Pentraxin‐3 in chronic heart failure: the CORONA and GISSI‐HF trials
Open Access
- 1 September 2012
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 14 (9), 992-999
- https://doi.org/10.1093/eurjhf/hfs092
Abstract
Aims Pentraxin‐3 (PTX3) is a component of the humoral arm of innate immunity which can regulate inflammatory processes. Since the role of inflammation in the progression of chronic heart failure (HF) is debated, we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF. Methods and results Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) and 1233 patients enrolled in the GISSI‐Heart Failure trial (GISSI‐HF). The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors, high sensitivity C‐reactive protein (hsCRP), and N‐terminal pro brain natriuretic peptide (NT‐proBNP). PTX3 concentration [median (Q1–Q3) = 5.34 (3.55–7.64) ng/mL, n = 2690] was higher in females, in older patients, and those with lower body mass index. Baseline elevated PTX3 was associated with a higher risk of all‐cause mortality [759 events, hazard ratio (HR) for 1 SD increase 1.20, 95% confidence interval (CI) 1.12–1.30, P < 0.0001], cardiovascular mortality (587 events, HR 1.27, 95% CI 1.17–1.38, P < 0.0001), or hospitalization for worsening HF (720 events, HR 1.21, 95% CI 1.12–1.30, P < 0.0001), and marginally improved discrimination. Three‐month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT‐proBNP. Rosuvastatin lowered hsCRP levels but significantly raised PTX3. Conclusion In two independent clinical trials that enrolled patients with chronic HF, PTX3 was consistently associated with outcomes. The opposite effects of a statin on hsCRP and PTX3 call for further investigation. Trial registration NCT00336336 (GISSI‐HF), NCT00206310 (CORONA).This publication has 29 references indexed in Scilit:
- C-Reactive ProteinHypertension, 2011
- Statins Enhance Formation of Phagocyte Extracellular TrapsCell Host & Microbe, 2010
- Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of AtherosclerosisNephrology Dialysis Transplantation, 2010
- Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Circulation, 2009
- Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause DeathArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Rosuvastatin in Older Patients with Systolic Heart FailureThe New England Journal of Medicine, 2007
- The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular trapsThe Journal of Experimental Medicine, 2007